Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT)

OBJECTIVES: To assess the efficacy and safety of a treatment switch from a twice-daily (BID) regimen containing zidovudine (ZDV) and lamivudine (3TC) plus a third agent to a once daily (QD) regimen containing the fixed-dose combination of tenofovir DF/emtricitabine (TDF/FTC, Truvada(®)) plus a diver...

Descripción completa

Detalles Bibliográficos
Autores principales: Arasteh, K, Weitner, L, Fenske, S, Kuhlmann, B, Freiwald, M, Ebrahimi, R, Gallo, L, Ranneberg, B, Mertenskoetter, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351977/
https://www.ncbi.nlm.nih.gov/pubmed/19541575
http://dx.doi.org/10.1186/2047-783X-14-5-195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351977/
https://www.ncbi.nlm.nih.gov/pubmed/19541575
http://dx.doi.org/10.1186/2047-783X-14-5-195

Ejemplares similares